MT
Therapeutic Areas
Renovion Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ARINA-1 (RVN-301) | Non-Cystic Fibrosis Bronchiectasis (NCFBE) | Phase 2 |
Leadership Team at Renovion
DC
Dan Copeland
Chief Executive Officer
CD
Carolyn Durham, PhD
Chief Scientific Officer
MZ
Marty Zamora, MD
Chief Medical Officer
HC
Hal Craig
Head of Chemistry, Manufacturing, and Controls Strategy and Operations
DW
Derek Winstanly, MBChB
Chairman of the Board